FDA Finds Pfizer-BioNTech COVID Vaccine Candidate Is 95% Effective

The transcript discusses the FDA's analysis of Pfizer's COVID-19 vaccine, highlighting its 95% efficacy after two doses and some protection after one dose. It explains the mRNA technology used in the vaccine and common side effects. The FDA's review process and emergency use authorization are detailed, along with the need for safety follow-ups. The transcript concludes with current COVID-19 statistics in the US.

What is the reported effectiveness of Pfizer's COVID-19 vaccine after two doses?

• 95%

• 90%

• 99%

• 85%

What new technology does Pfizer's vaccine use to trigger an immune response?

• Messenger RNA

• Protein Subunit

• DNA

• Viral Vector

Which age group is more likely to experience side effects from the Pfizer vaccine?

• 55 and older

• 35-54

• 18-34

• Under 18

What is a major discussion point for the FDA's emergency use authorization of the Pfizer vaccine?

• Placebo group access to the vaccine

• Vaccine distribution logistics

• Vaccine pricing

• Vaccine storage requirements

How many Americans are reported to be in the hospital with COVID-19 according to the latest data?

• 150,000

• 120,000

• 100,000

• 50,000